Benjamin Koch

Benjamin Koch


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2020 in Nature
Verified
Journal Article
Closed access
PDF file
DBDenisa Bojkova
Denisa Bojkova
KKKevin Klann
Kevin Klann
BKBenjamin Koch
Benjamin Koch
MWMarek Widera
Marek Widera
DKDavid Krause
David Krause
CMChristian Münch
Christian Münch

1 April 2019 in Kidney International
Verified
Journal Article
Closed access
FHFabian Hammer
Fabian Hammer
UMUwe Malzahn
Uwe Malzahn
JDJulian Donhauser
Julian Donhauser
CBChristoph Betz
Christoph Betz
MSMarkus P. Schneider
Markus P. Schneider
JZJosef Zimmermann
Josef Zimmermann

12 April 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
CCChengcong Cai
Chengcong Cai
BKBenjamin Koch
Benjamin Koch
KMKenichi Morikawa
Kenichi Morikawa
GSGoki Suda
Goki Suda
NSNaoya Sakamoto
Naoya Sakamoto
CLChristian Lange
Christian Lange
Extracellular vesicles (EVs) are increasingly recognized as important mediators of intercellular communication. In this study, we aimed to further characterize the role of macrophage-derived EVs in immune responses against hepatitis C virus (HCV) and the potential of polyunsaturated fatty acids (PUFAs) to modulate this modality of innate immunity. To this end, EVs were isolated from interferon-stimulated macrophage cultures or from serum of patients with acute or chronic hepatitis C. EVs were characterized by electron microscopy, flow cytometry, RNA-sequencing, and Western blot analysis. The effect of EVs on replication of HCV was assessed in coculture models. Functional analyses were performed to assess the impact of PUFAs on EV-mediated antiviral immunity. We found that macrophages secreted various cytokines shortly after stimulation with type I and II IFN, which orchestrated a fast but short-lasting antiviral state. This rapid innate immune answer was followed by the production of macrophage-derived EVs, which induced a late, but long-lasting inhibitory effect on HCV replication. Of note, exposure of macrophages to PUFAs, which are important regulators of immune responses, dampened EV-mediated antiviral immune responses. Finally, EVs from patients with hepatitis C exhibited long-lasting antiviral activities during IFN therapy as well. The antiviral effect of EVs from Caucasian and Japanese patients differed, which may be explained by different nutritional uptake of PUFAs. In conclusion, our data indicate that macrophage-derived EVs mediate long-lasting inhibitory effects on HCV replication, which may bridge the time until efficient adaptive immune responses are established, and which can be blunted by PUFAs.

1 January 2014 in Blood Purification
Verified
Journal Article
Open access
PDF file
SBStefan Büttner
Stefan Büttner
BKBenjamin Koch
Benjamin Koch
ODOlga Dolnik
Olga Dolnik
MEMarkus Eickmann
Markus Eickmann
TFTilo Freiwald
Tilo Freiwald
HGHelmut Geiger
Helmut Geiger
Therapeutic options for Ebola virus disease (EVD) are currently limited to (1) best supportive care, and (2) evolving virus-specific therapies, resulting from decades of analyzing one of the world's deadliest diseases. Supportive care ranges from oral or intravenous rehydration therapy and anti-emetics in developing countries to much more extensive life-support interventions in resource-rich countries. Current EVD-specific therapies attempt to either interfere with the earliest steps of viral replication or to elicit a strong immune response against the virus. An entirely new approach is the extracorporeal elimination of viruses and viral glycoproteins by lectin affinity plasmapheresis. Herein, we report for the first time the successful and safe use of lectin affinity plasmapheresis in a patient with severe Ebola virus disease.

29 October 2019 in Cells
Verified
Journal Article
Open access
PDF file
PBPatrick C. Baer
Patrick C. Baer
BKBenjamin Koch
Benjamin Koch
EHElena Hickmann
Elena Hickmann
RSRalf Schubert
Ralf Schubert
JCJindrich CInatl
Jindrich CInatl
HGHelmut Geiger
Helmut Geiger
Mesenchymal stromal/stem cells (MSCs) are immature multipotent cells, which represent a rare population in the perivascular niche within nearly all tissues. The most abundant source to isolate MSCs is adipose tissue. Currently, perirenal adipose tissue is rarely described as the source of MSCs. MSCs were isolated from perirenal adipose tissue (prASCs) from patients undergoing tumor nephrectomies, cultured and characterized by flow cytometry and their differentiation potential into adipocytes, chondrocytes, osteoblasts and epithelial cells. Furthermore, prASCs were stimulated with lipopolysaccharide (LPS), lipoteichoic acid (LTA) or a mixture of cytokines (cytomix). In addition, prASC susceptibility to human cytomegalovirus (HCMV) was investigated. The expression of inflammatory readouts was estimated by qPCR and immunoassay. HCMV infection was analyzed by qPCR and immunostaining. Characterization of cultured prASCs shows the cells meet the criteria of MSCs and prASCs can undergo trilineage differentiation. Cultured prASCs can be induced to differentiate into epithelial cells, shown by cytokeratin 18 expression. Stimulation of prASCs with LPS or cytomix suggests the cells are capable of initiating an inflammation-like response upon stimulation with LPS or cytokines, whereas, LTA did not induce a significant effect on the readouts (ICAM-1, IL-6, TNFα, MCP-1 mRNA and IL-6 protein). HCMV broadly infects prASCs, showing a viral load dependent cytopathological effect (CPE). Our current study summarizes the isolation and culture of prASCs, clearly characterizes the cells, and demonstrates their immunomodulatory potential and high permissiveness for HCMV.

26 April 2018 in Blood Purification
Verified
Journal Article
Open access
PDF file
BKBenjamin Koch
Benjamin Koch
PSPatricia Schult-Dietrich
Patricia Schult-Dietrich
SBStefan Büttner
Stefan Büttner
BDBijan Dilmaghani
Bijan Dilmaghani
DLDario Lohmann
Dario Lohmann
HGHelmut Geiger
Helmut Geiger
Background/Aims: Middle East respiratory syndrome coronavirus (MERS-CoV) and Marburg virus (MARV) are among the World Health Organization’s top 8 emerging pathogens. Both zoonoses share nonspecific early symptoms, a high lethality rate, and a reduced number of specific treatment options. Therefore, we evaluated extracorporeal virus and glycoprotein (GP) elimination by lectin affinity plasmapheresis (LAP). Methods: For both MERS-CoV (pseudovirus) as well as MARV (GPs), 4 LAP devices (Mini Hemopurifiers, Aethlon Medical, San Diego, CA, USA) and 4 negative controls were tested. Samples were collected every 30 min and analyzed for reduction in virus infectivity by a flow cytometry-based infectivity assay (MERS-CoV) and in soluble GP content (MARV) by an immunoassay. Results: The experiments show a time-dependent clearance of MERS-CoV of up to 80% within 3 h (pseudovirus). Up to 70% of MARV-soluble GPs were eliminated at the same time. Substantial saturation of the binding resins was detected within the first treatment hour. Conclusion: MERS-CoV (pseudovirus) and MARV soluble GPs are eliminated by LAP in vitro. Considering the high lethality and missing established treatment options, LAP should be evaluated in vivo. Especially early initiation, continuous therapy, and timed cartridge exchanges could be of importance.